SCHEMBL6941297

SCHEMBL6941297

O=C(OC1CCC(Nc2ccc([N+](=O)[O-])cc2C(=O)NCc2ccccc2)C1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
THRB P10828 1/20 0.47
KMT2A Q03164 6/20 0.45
MEN1 O00255 4/20 0.45
BCHE P06276 2/20 0.45
GAA P10253 2/20 0.45
ALDH1A1 P00352 2/20 0.44
AKR1C3 P42330 1/20 0.44
CYP2C19 P33261 2/20 0.43
POLB P06746 1/20 0.43
CYP2C9 P11712 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
HPGD P15428 1/20 0.42
FFAR1 O14842 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PKM P14618 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6941778 0.86 MAPT (0.63) MAPTTHRBKMT2AMEN1GAA
SCHEMBL6940165 0.84 MAPT (0.46) MAPTKMT2AMEN1GAASMN1; SMN2
SCHEMBL6940168 0.84 MAPT (0.46) MAPTKMT2AMEN1GAASMN1; SMN2
SCHEMBL6937019 0.84 MAPT (0.54) MAPTTHRBKMT2AMEN1GAA
SCHEMBL6940697 0.84 ALDH1A1 (0.56) MAPTKMT2AMEN1ALDH1A1POLB
SCHEMBL7369386 0.84 MAPT (0.45) MAPTTHRBKMT2AMEN1ALDH1A1
SCHEMBL6940696 0.84 ALDH1A1 (0.56) MAPTKMT2AMEN1ALDH1A1POLB
SCHEMBL7369389 0.84 MAPT (0.45) MAPTTHRBKMT2AMEN1ALDH1A1
SCHEMBL6938843 0.82 MAPT (0.44) MAPTKMT2AMEN1GAASMN1; SMN2
SCHEMBL6940097 0.82 LMNA (0.46) MAPTKMT2AMEN1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP claimed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US claimed
CN-1305454-A Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase FUJISAWA PHARMACEUTICAL CO (JP) 2001-07-25 CN claimed
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP disclosed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed
CN-1305454-A Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase FUJISAWA PHARMACEUTICAL CO (JP) 2001-07-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A MAPT 4706/4885THRB 4022/4885KMT2A 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.